FHD-909 Stops Before Expansion
Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and will also stop their selective SMARCA2 degrader program. Foghorn disclosed an approximately 40% workforce reduction and said it will…
